News
ALKS
41.52
+3.96%
1.58
Assessing Alkermes (ALKS) Valuation After New Clinical And Real World Data On Key Psychiatry Drugs
Simply Wall St · 18h ago
Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
TipRanks · 19h ago
Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)
TipRanks · 3d ago
Alkermes presents Phase 2 Vibrance-1 data on alixorexton in narcolepsy type 1 at ASCP meeting
PUBT · 3d ago
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Barchart · 3d ago
Weekly Report: what happened at ALKS last week (0518-0522)?
Weekly Report · 4d ago
Alkermes presents real-world study comparing Lybalvi versus olanzapine adherence, relapse proxies
PUBT · 05/21 11:01
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Barchart · 05/21 06:00
Alkermes Shareholders Approve Amended Stock Incentive Plan
TipRanks · 05/20 20:36
Alkermes shareholders approve 2018 stock plan share increase by 5.9 million
PUBT · 05/20 20:11
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge
TipRanks · 05/20 00:33
Weekly Report: what happened at ALKS last week (0511-0515)?
Weekly Report · 05/18 10:24
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline
TipRanks · 05/15 16:32
Why Alkermes (ALKS) Is Up 10.2% After Positive Phase 3 LUMRYZ Idiopathic Hypersomnia Data
Simply Wall St · 05/14 05:27
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)
TipRanks · 05/14 01:50
Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)
TipRanks · 05/13 11:30
Alkermes Price Target Raised to $48.00/Share From $45.00 by Baird
Dow Jones · 05/13 11:26
Alkermes Is Maintained at Outperform by Baird
Dow Jones · 05/13 11:26
Baird Maintains Outperform on Alkermes, Raises Price Target to $48
Benzinga · 05/13 11:16
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Benzinga · 05/12 18:27
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.